Investor Brand Network – 1 hour ago<\/p>\n
![\"\"\/](\"https:\/\/barchart-news-media-prod.aws.barchart.com\/FC\/c99e7bbddcee3da16f77218bcf524a51\/vrxa.png\")
Novartis has agreed to\u00a0acquire\u00a0Myricx\u00a0Bio for\u00a0$1.1 billion\u00a0upfront, with up to $400 million in milestone payments, reinforcing strong pharmaceutical demand for next-generation antibody-drug conjugate (\u201cADC\u201d) technologies.\u00a0\u00a0The latest transaction adds to a growing list of multibillion-dollar ADC and T-cell engager (\u201cTCE\u201d) deals, highlighting continued strategic investment in differentiated antibody platforms.\u00a0<\/p>\n
VERAXA Biotech (NASDAQ: VRXA)<\/a>\u00a0operates in one\u00a0of biotechnology\u2019s most active partnering environments<\/a>, with pharmaceutical companies continuing to commit billions of dollars to differentiated antibody therapeutics. The latest example came this week as\u00a0Novartis agreed to acquire\u00a0Myricx\u00a0Bio<\/a>\u00a0for\u00a0$1.1 billion\u00a0upfront, plus up to $400 million in milestone payments, to gain access to the company\u2019s novel N-myristoyltransferase\u00a0inhibitor (\u201cNMTi\u201d) payload platform and two lead ADC programs. The acquisition reflects continued industry demand for innovative antibody technologies capable of addressing limitations of existing cancer therapies.<\/p>\n The Novartis transaction follows a series of major antibody therapeutics deals, including\u00a0Jazz Pharmaceuticals\u2019 collaboration with\u00a0AbCellera<\/a>,\u00a0Gilead Sciences\u2019 acquisition of\u00a0Tubulis<\/a>\u00a0and multiple multibillion-dollar ADC licensing agreements. VERAXA is advancing proprietary antibody therapeutics spanning both ADCs and TCEs through its patented\u00a0BiTAC\u00a0platform<\/a>, positioning the company within two therapeutic categories that continue to attract significant pharmaceutical investment, strategic\u00a0collaborations\u00a0and acquisition activity.<\/p>\n About VERAXA Biotech AG<\/p>\n At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific\u00a0ADCs\u00a0and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary\u00a0BiTAC\u00a0formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and\u00a0cutting-edge\u00a0technology.<\/p>\n BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.<\/p>\n NOTE TO INVESTORS:\u00a0IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit\u00a0https:\/\/www.InvestorBrandNetwork.com<\/a><\/p>\n Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:\u00a0http:\/\/IBN.fm\/Disclaimer<\/a><\/p>\n The latest news and updates relating to VRXA are available in the company\u2019s newsroom at\u00a0https:\/\/ibn.fm\/VRXA<\/a><\/p>\n Corporate Communications<\/p>\n IBN This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Investor Brand Network – 1 hour ago Novartis has agreed to\u00a0acquire\u00a0Myricx\u00a0Bio for\u00a0$1.1 billion\u00a0upfront, with up to $400 million…\n","protected":false},"author":2,"featured_media":99144,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[432,49080,5429,429,428,431,430,433,206,436],"class_list":["post-99143","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-futures","tag-gild","tag-gilead-sciences-inc","tag-index-market-quote","tag-index-market-quotes","tag-index-market-symbol","tag-index-market-symbols","tag-indices","tag-novartis","tag-the-globe-and-mail"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116879779902058983","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/99143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=99143"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/99143\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/99144"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=99143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=99143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=99143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Austin, Texas
www.InvestorBrandNetwork.com<\/a>
512.354.7000 Office
Editor@InvestorBrandNetwork.com<\/a><\/p>\n